Neurorive develops  rapid-acting antidepressants and cognitive enhancers based on improving brain plasticity and reducing neuroinflammation.

Neurorive aims to become a powerful drug screening platform through the development of new drugs along with neurophysiology and brain science.

Neurorive has been developing a new drug for central neurological and psychiatric diseases since its establishment in 2019.

Starting with the development of treatments for dementia and depression, we are also building a lineup of new PTSD drugs.